Bolt Biotherapeutics (BOLT) Other Accumulated Expenses (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Other Accumulated Expenses of $410000.0 for Q1 2026, up 42.36% sequentially from $288000.0 in Q4 2025, and down 22.05% YoY from $526000.0 in Q1 2025.
Bolt Biotherapeutics (BOLT) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $410000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 22.05% year-over-year to $410000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $410000.0 (down 22.05% YoY) and the FY2025 annual result came in at $288000.0, down 24.21% from the prior year.
- Other Accumulated Expenses advanced to $410000.0 in Q1 2026 per BOLT's latest filing, from $288000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $2.0 million in Q1 2022 and troughed at $288000.0 in Q4 2025.
- A 5-year average of $746882.4 and a median of $574000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses jumped 140.54% in 2022, then tumbled 56.07% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $963000.0 in 2022, then sank by 40.39% to $574000.0 in 2023, then plunged by 33.8% to $380000.0 in 2024, then slipped by 24.21% to $288000.0 in 2025, then soared by 42.36% to $410000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $410000.0, $288000.0, and $385000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 563,000.00 |
| Mar 31, 2026 | 410,000.00 |
| Dec 31, 2025 | 288,000.00 |
| Sep 30, 2025 | 385,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 380,000.00 |
| Sep 30, 2024 | 373,000.00 |
| Jun 30, 2024 | 446,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Dec 31, 2023 | 574,000.00 |
| Sep 30, 2023 | 849,000.00 |
| Jun 30, 2023 | 826,000.00 |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 963,000.00 |
| Sep 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 906,000.00 |
| Mar 31, 2022 | 1.96 Mn |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 837,000.00 |